Sunday, February 14, 2016 6:23:42 PM
Regarding that patent persuit, I did not recognize Revimmune (shown towards the top, together with COGNATE BIOSERVICES, INC. , NORTHWEST BIOTHERAPEUTICS , The Regents of the University of California ).
Revimmune (Trademark)... Paris, France.
Owner: Linda Powers.
trademark.markify.com/trademarks/ctm/revimmune/013303201
In International Class 5:
Biological and pharmaceutical preparations, namely biological and pharmaceutical preparations and substances for the prevention and treatment of blood disease and cancer, viral and other infectious diseases, and the modulation and treatment of immune system related diseases and disorders.
In International Class 42:
Research and development of biologicals and pharmaceuticals in the prevention and treatment of blood disease and cancer, viral and other infectious diseases, and the modulation and treatment of immune system related diseases and disorders.
OR:
Is this a different Revimmune?
"Cytheris changed its name to Revimmune SAS" (01 Jul 2015)
http://adisinsight.springer.com/drugs/800020133
related to Interleukin-7
such as:
https://clinicaltrials.gov/ct2/show/NCT02659800
IL-7 in Increasing Low CD4 Counts After Concurrent Radiation and Temozolomide Treatment in Patients With High Grade Gliomas
Sponsors and Collaborators:
Sidney Kimmel Comprehensive Cancer Center
National Cancer Institute (NCI)
Revimmune
The patent also mentioned "Ganjel; James Kelly"
Looks like he is with Toucan.
Revimmune (Trademark)... Paris, France.
Owner: Linda Powers.
trademark.markify.com/trademarks/ctm/revimmune/013303201
In International Class 5:
Biological and pharmaceutical preparations, namely biological and pharmaceutical preparations and substances for the prevention and treatment of blood disease and cancer, viral and other infectious diseases, and the modulation and treatment of immune system related diseases and disorders.
In International Class 42:
Research and development of biologicals and pharmaceuticals in the prevention and treatment of blood disease and cancer, viral and other infectious diseases, and the modulation and treatment of immune system related diseases and disorders.
OR:
Is this a different Revimmune?
"Cytheris changed its name to Revimmune SAS" (01 Jul 2015)
http://adisinsight.springer.com/drugs/800020133
related to Interleukin-7
such as:
https://clinicaltrials.gov/ct2/show/NCT02659800
IL-7 in Increasing Low CD4 Counts After Concurrent Radiation and Temozolomide Treatment in Patients With High Grade Gliomas
Sponsors and Collaborators:
Sidney Kimmel Comprehensive Cancer Center
National Cancer Institute (NCI)
Revimmune
The patent also mentioned "Ganjel; James Kelly"
Looks like he is with Toucan.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
